These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 29976748

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Mani R, Rajgolikar G, Nunes J, Zapolnik K, Wasmuth R, Mo X, Byrd JC, Lee DA, Muthusamy N, Vasu S.
    Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
    [Abstract] [Full Text] [Related]

  • 23. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
    Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS.
    Clin Cancer Res; 2013 Jul 15; 19(14):3844-55. PubMed ID: 23690482
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
    Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, Wei A, Ramshaw HS, Powell JA, Lopez AF, Lewis ID, McCall MN, Lock RB.
    Haematologica; 2015 Jul 15; 100(7):914-26. PubMed ID: 26130514
    [Abstract] [Full Text] [Related]

  • 25. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Yan B, Chen Q, Shimada K, Tang M, Li H, Gurumurthy A, Khoury JD, Xu B, Huang S, Qiu Y.
    Leukemia; 2019 Apr 15; 33(4):931-944. PubMed ID: 30291336
    [Abstract] [Full Text] [Related]

  • 26. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker.
    Abdollahpour-Alitappeh M, Razavi-Vakhshourpour S, Abolhassani M.
    Biotechnol Appl Biochem; 2018 Nov 15; 65(6):841-847. PubMed ID: 29972607
    [Abstract] [Full Text] [Related]

  • 27. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
    Wang ZZ, Lu Y, Xu YX, Xing HY, Tang KJ, Tian Z, Rao Q, Wang M, Xiong DS, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar 14; 41(3):192-197. PubMed ID: 32311887
    [Abstract] [Full Text] [Related]

  • 28. CD123 bi-specific antibodies in development in AML: What do we know so far?
    Slade MJ, Uy GL.
    Best Pract Res Clin Haematol; 2020 Dec 14; 33(4):101219. PubMed ID: 33279175
    [Abstract] [Full Text] [Related]

  • 29. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
    Xie LH, Biondo M, Busfield SJ, Arruda A, Yang X, Vairo G, Minden MD.
    Blood Cancer J; 2017 Jun 02; 7(6):e567. PubMed ID: 28574487
    [Abstract] [Full Text] [Related]

  • 30. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 31. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E.
    Br J Haematol; 2013 May 27; 161(3):389-401. PubMed ID: 23432359
    [Abstract] [Full Text] [Related]

  • 32. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T.
    Proc Natl Acad Sci U S A; 2015 Aug 25; 112(34):10786-91. PubMed ID: 26261316
    [Abstract] [Full Text] [Related]

  • 33. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
    Lo TH, Abadir E, Gasiorowski RE, Kabani K, Ramesh M, Orellana D, Fromm PD, Kupresanin F, Newman E, Cunningham I, Hart DNJ, Silveira PA, Clark GJ.
    PLoS One; 2019 Aug 25; 14(5):e0216368. PubMed ID: 31075107
    [Abstract] [Full Text] [Related]

  • 34. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
    Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.
    Mol Cancer Ther; 2018 Feb 25; 17(2):554-564. PubMed ID: 29142066
    [Abstract] [Full Text] [Related]

  • 35. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S.
    Mol Ther; 2016 Sep 29; 24(9):1615-26. PubMed ID: 27401038
    [Abstract] [Full Text] [Related]

  • 36. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
    Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.
    Blood; 2016 Jan 07; 127(1):122-31. PubMed ID: 26531164
    [Abstract] [Full Text] [Related]

  • 37. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
    Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, Manni S, Guercio M, Pezzella M, Iaffaldano L, Silvestris DA, Sinibaldi M, Di Cecca S, Pitisci A, Velardi E, Merli P, Algeri M, Lodi M, Paganelli V, Serafini M, Riminucci M, Locatelli F, Quintarelli C.
    J Hematol Oncol; 2022 Nov 05; 15(1):163. PubMed ID: 36335396
    [Abstract] [Full Text] [Related]

  • 38. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM.
    Leuk Res; 2014 Nov 05; 38(11):1367-73. PubMed ID: 25278187
    [Abstract] [Full Text] [Related]

  • 39. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.
    Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK.
    Blood; 2014 Feb 20; 123(8):1218-28. PubMed ID: 24363400
    [Abstract] [Full Text] [Related]

  • 40. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B, Perkins B, Karantanos T, Levis M, Ghiaur G, Smith BD, Jones RJ.
    Leuk Res; 2020 Dec 20; 99():106477. PubMed ID: 33220589
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.